Tag: Dana-Farber Cancer Institute
![arthur t sands md phd president and chief executive officer lexicon pharmaceuticals5](https://www.carcinoid.org/wp-content/uploads/2010/09/arthur-t-sands-md-phd-president-and-chief-executive-officer-lexicon-pharmaceuticals5.jpg)
Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients
September 10, 2010
Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032). The trial has been given Fast Track status in the U.S. and …
READ MORE![clinical trials rss logo](https://www.carcinoid.org/wp-content/uploads/2010/06/clinical-trials-rss-logo.gif)
Clinical Trials Resources for Carcinoid Cancer & Neuroendocrine Tumor Patients
June 13, 2010
Carcinoid and neuroendocrine tumor patients can have the latest information about clinical trials delivered directly to their computers – by RSS feed or e-mail. Go to https://clinicaltrials.gov/, in the search field enter the type of trial you are…
READ MORE